secwatch.observer — SEC 8-K summary
======================================

Issuer:     Royalty Pharma plc (RPRX)
CIK:        0001802768
Form:       8-K
Filed at:   2022-12-01T23:59:59+00:00
Accession:  0001193125-22-296619
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 2.06
LLM model:  deepseek-v4-flash:cloud@v2

Royalty Pharma records $273.6M impairment on gantenerumab royalty after Roche halts trials
--------------------------------------------------------------------------------

- Non-cash impairment charge of $273.6M related to gantenerumab financial royalty asset.
- Roche discontinued gantenerumab trials Nov 30, 2022 after GRADUATE I/II missed primary endpoint.
- Impairment reflects entire net carrying value as of Sept 30, 2022; no impact on non-GAAP results.
- No portion of the charge relates to future cash expenditures.
- Charge will be recorded in Q4 2022 under GAAP.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1802768/000119312522296619/0001193125-22-296619-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1802768/000119312522296619/d432184d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-296619

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer